Evidence map›Paper›PMID 41537428›Full record

ArticleThe Cochrane database of systematic reviews2026

Anti-vascular endothelial growth factor (anti-VEGF) agents for neovascular age-related macular degeneration (nAMD): a network meta-analysis.

Ersilia Lucenteforte, Sueko M Ng, Rosella Saulle, Geraldine Hoad, Robert Schillinger, Gianni Virgili

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Cochrane database of systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Special Issue: Molecular Mechanisms and Treatment of Retinal Diseases.International journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ersilia LucenteforteDepartment of Statistics, Computer Sciences and Applications "G. Parenti", University of Florence, Florence, Italy.
Sueko M NgDepartment of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Rosella SaulleDepartment of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Geraldine HoadResearch, Macular Society, Andover, UK.
Robert SchillingerResearch, Macular Society, Andover, UK.
Gianni VirgiliDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.ORCID 0000-0002-9960-2989

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the comparative efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) agents and their biosimilars for people with neovascular age-related macular degeneration (nAMD), and provide a relative ranking of interventions using network meta-analysis (NMA) methods, considering differences in treatment intensity.

Indexed as

Angiogenesis InhibitorsBiosimilar PharmaceuticalsMacular DegenerationVascular Endothelial Growth Factor AAntibodies, Monoclonal, HumanizedBevacizumabHumansNetwork Meta-Analysis as TopicRandomized Controlled Trials as TopicRanibizumabAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBiosimilar PharmaceuticalsRanibizumabVascular Endothelial Growth Factor A

Identifiers

PMID41537428
PMCPMC12805632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.